Immix Biopharma Appoints Michael Grabow As Chief Commercial Officer To Lead Global Launch Of NXC-201 For Relapsed/Refractory AL Amyloidosis

Immix Biopharma, Inc., a global leader in developing therapies for relapsed and refractory AL Amyloidosis, has announced the appointment of Michael Grabow as Chief Commercial Officer. In this role, he will oversee all aspects of commercialization and launch activities for NXC-201, the company’s lead candidate for treating relapsed/refractory AL Amyloidosis.

Michael Grabow brings over 25 years of experience in biopharmaceutical commercialization. Before joining Immix Biopharma, he served as Head of Commercial Operations at Chimerix, Inc., where he led the go-to-market strategy and launch of MODEYSO® (dordaviprone), the first FDA-approved therapy for H3 K27M-mutant diffuse midline glioma, an ultra-rare and aggressive brain tumor. MODEYSO® received accelerated approval in 2025 based on clinical data from multiple open-label studies, and Chimerix was later acquired by Jazz Pharmaceuticals for $935 million. 

Prior to his tenure at Chimerix, Grabow held executive positions at Spectrum Pharmaceuticals (acquired by Assertio) and various commercial and marketing roles at Amgen. He has successfully contributed to more than ten commercial drug launches throughout his career. Grabow holds an MBA from Pepperdine University and a BS from California State University.

Commenting on the appointment, Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma, stated, “AL amyloidosis is a devastating disease that leads to organ failure and death. We believe that NXC-201 is uniquely positioned to save lives by addressing a critical unmet need in relapsed/refractory AL amyloidosis.” Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Michael’s appointment will accelerate the commercialization of NXC-201 and support our efforts to deliver what we believe could be the first approved therapy for this condition.”

Expressing enthusiasm about his new role, Grabow said, “Leading the NXC-201 launch is an especially exciting opportunity. The clinical data are compelling, and with FDA designations such as Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD), NXC-201 has the potential to transform treatment for a deadly disease that currently has no approved therapies. I’m thrilled to work with the Immix team as the company advances toward becoming a fully commercial-stage organization.”